Client and commerical-phase bioelectronic life sciences innovator Tivic Health Systems closed an initial public offering for a gross of $15 million to grow sales of its ClearUP® Sinus Relief (“ClearUP”) device. ClearUP® is a patented handheld device that uses ultra-low current electrical waves to relieve symptoms of sinus and nasal inflammation. The U.S. Food and Drug Administration categorizes it as a Class II and the European Union as a Class IIa medical device, and it has received three regulatory clearances.

Based in Silicon Valley, Tivic has been a client of Procopio since nearly its inception. Our Capital Markets and Securities attorneys including Caitlin Murphey guided the IPO.

Learn more in Tivic’s press release.